Skip to main content
ZYME logo

ZYME · Zymeworks Inc. · Investor Relations

Track ZYME — free
$26.00 -0.04 (-0.15%) Play latest call Q1 2026 earnings call transcript
Market Cap
$1.80B
Shares
69.03M
Volume · Nov 18 1.09M Avg daily vol (3M) 1.08M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2027-02-11 00:00 UTC Zymeworks R&D Day 2026 Event

Recent news

Date Headline
2026-11-16 Zymeworks Announces $200 Million Share Repurchase Authorization
2026-11-09 Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-10-24 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels Confirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant

2026-10-23 Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones Zymeworks also eligible to receive tiered high-single-digit to mid-teen

2026-10-19 Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

VANCOUVER, British Columbia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been

2026-10-15 Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,

2026-09-28 Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI ® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR Zymeworks to

2026-09-23 Zymeworks Completes Acquisition of Theravance Biopharma

Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of

2026-08-25 U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEA Second FDA approval for zanidatamab in less than two years further validates Zymeworks’

2026-08-11 Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in

2026-08-06 Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones Acquisition of Theravance Biopharma, Inc. expected to close in 2H 2026, adding durable

2026-07-16 Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its

2026-06-29 Zymeworks to Acquire Theravance Biopharma, Inc.

Acquisition adds YUPELRI ® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing

2026-06-14 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients (

2026-05-14 Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has

2026-05-13 Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in

2026-05-07 Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026 China’s NMPA has

2026-04-21 Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum resistant ovarian cancer Median duration of response was not reached at the time

Past events

Date Event Type
2026-11-17 Jefferies Global Healthcare Conference in London Conference
2026-11-17 2026 Jefferies Global Healthcare Conference Conference
2026-11-12 Truist Securities BioPharma Symposium Conference
2026-11-11 Stifel 2026 Healthcare Conference Conference
2026-11-10 8th Annual Wolfe Research Healthcare Conference Conference
2026-10-27 Zymeworks Portfolio Update Event
2026-09-28 Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition Earnings call
2026-09-28 Theravance Biopharma Closing Conference Call Conference
2026-09-15 H.C. Wainwright Annual Global Investment Conference Conference
2026-09-14 Morgan Stanley Healthcare Conference Conference
2026-09-09 Citi’s Biopharma Back to School Summit Event
2026-09-08 Wells Fargo Healthcare Conference Conference
2026-06-29 Zymeworks’ Acquisition of Theravance Biopharma Webcast
2026-06-03 2026 Jefferies Global Healthcare Conference Conference
2026-05-27 TD Cowen 7th Annual Oncology Innovation Summit Event
2026-05-20 2026 Stifel Virtual Targeted Oncology Forum Webcast
2026-05-07 Zymeworks First Quarter 2026 Results Conference Call Earnings call
2026-04-21 2026 Bloom Burton & Co. Healthcare Investor Conference Conference
2026-04-15 Needham 25th Annual Virtual Healthcare Conference Conference
2026-03-11 Citizens Life Science Conference Conference
2026-03-09 Leerink Annual Global Healthcare Conference Conference
2026-03-02 TD Cowen 46th Annual Health Care Conference Conference
2026-03-02 Zymeworks Fourth Quarter 2025 Results Conference Call Earnings call

Source: https://ir.zymeworks.com/

Key facts CIK 1937653 CUSIP 98985Y108 13F (30d) 206 filings 192 filers Visit website Investor relations